The share acquisitions announced by Orion Corporation on 27 April 2016 have been completed. The Company has purchased during the time period from 3 June 2016 to 15 June 2016 through public trading in accordance with the rules of on the Nasdaq Helsinki Ltd. a total of 500,000 Company's own B shares at an average price per share of approximately EUR 33.5319. The total purchase price paid for the shares was EUR 16,765,946.50.
After the repurchases, the Company holds a total of 783,366 own B shares corresponding to approximately 0.55% of the total number of the shares and 0.09% of the votes.
| Timo Lappalainen
President and CEO
| Olli Huotari
SVP, Corporate Functions
Tuukka Hirvonen, Communications Manager, Financial Communications & Investor Relations
tel. +358 10 426 2721
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2015 amounted to EUR 1,016 million and the Company had about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.